MUKUNDAM VEERABATHINI: Open Payments
NPI 1306981964 · STATE COLLEGE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,980 in 96 payments from 10 companies in 2025. Trend: 2023 $2,033 · 2024 $1,206 · 2025 $1,980
Food & beverage: $1,980
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 26 | $513 |
| Otsuka America Pharmaceutical, Inc. | 18 | $492 |
| Neurocrine BioSciences, Inc. | 18 | $242 |
| Alkermes, Inc. | 9 | $187 |
| Teva Pharmaceuticals USA, Inc. | 9 | $181 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $109 |
| E.R. Squibb & Sons, L.L.C. | 4 | $96 |
| Janssen Pharmaceuticals, Inc | 4 | $78 |
| Axsome Therapeutics, Inc. | 2 | $58 |
| Lundbeck LLC | 1 | $22 |
Products named: CAPLYTA, INGREZZA, ABILIFY ASIMTUFII, REXULTI, ARISTADA, AUSTEDO XR, TRINTELLIX, COBENFY.
Industry payments across PA — which companies pay providers there.
